SCHEMBL3980375

SCHEMBL3980375

CC(C)(C)C1CCC2C(C1)C2C(=O)NCC(N)=O

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.33
FPR3 P25089 1/20 0.31
FPR2 P25090 1/20 0.31
EPHX1 P07099 1/20 0.30
GLA P06280 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3985896 0.80 EPHX1 (0.36) FPR3FPR2EPHX1
SCHEMBL3981105 0.77 EPHX1 (0.33) EPHX1
SCHEMBL6274699 0.76 GLA (0.46) EPHX1GLA
SCHEMBL3981066 0.76 POLB (0.41) SSTR4FPR3FPR2EPHX1
SCHEMBL3981127 0.76 POLB (0.37) SSTR4FPR3FPR2
SCHEMBL3979934 0.74 POLB (0.40) SSTR4FPR3FPR2EPHX1
SCHEMBL3981834 0.74 POLB (0.40) SSTR4FPR3FPR2EPHX1
SCHEMBL3984200 0.73 FPR3 (0.35) FPR3FPR2
SCHEMBL13240197 0.73 FPR3 (0.35) FPR3FPR2
SCHEMBL3984148 0.72 EPHX1 (0.34) EPHX1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562575-B1 FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY ABBOTT LAB (US) 2009-05-20 EP claimed
EP-1562575-A1 FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY Abbott Laboratories (US) 2005-08-17 EP claimed
US-20040209859-A1 Fused cycloalkyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-10-21 US claimed
WO-2004037241-A1 FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY ABBOTT LABORATORIES (US) 2004-05-06 WO claimed
US-20040077617-A1 Fused cycloalkyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-04-22 US claimed
EP-1562575-B1 FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY ABBOTT LAB (US) 2009-05-20 EP disclosed
EP-1562575-A1 FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY Abbott Laboratories (US) 2005-08-17 EP disclosed
US-20040209859-A1 Fused cycloalkyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-10-21 US disclosed
WO-2004037241-A1 FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY ABBOTT LABORATORIES (US) 2004-05-06 WO disclosed
US-20040077617-A1 Fused cycloalkyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209859-A1 Fused cycloalkyl amides and acids and their therapeutic applications GRIN2A, GRIK1, GRIN2B SSTR4 1644/4885FPR3 588/4885FPR2 507/4885
US-20040077617-A1 Fused cycloalkyl amides and acids and their therapeutic applications GRIN2A, GRIK1, GRIN2B SSTR4 1644/4885FPR3 588/4885FPR2 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.